Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $12.3 Million - $14.5 Million
55,500 Added 317.14%
73,000 $19.1 Million
Q1 2021

May 13, 2021

BUY
$207.02 - $241.31 $3.62 Million - $4.22 Million
17,500 New
17,500 $3.76 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.